Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Acquiring GATC Biotech

NEW YORK (GenomeWeb) – Sequencing services firm GATC Biotech said today it is being acquired by Eurofins Scientific.

The deal is expected to close in July 2017 and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. The purchase price was not disclosed.

"This transaction is a demonstration of Eurofins' commitment to genomics services," Eurofins CEO Gilles Martin said in a statement. "We believe that advances in gene sequencing will continue to drive innovations not only in clinical diagnostics, but in the broader bioanalytical testing market as well."

GATC has 140 employees at two sites and provides services to some 10,000 customers. The company's annual revenues are in the range of €20 million ($22.5 million).

"We are excited to be joining the Eurofins family of laboratories and look forward to the next phase of our development within the Group," Peter Pohl, GATC CEO and co-founder, said in a statement. "We are confident that with access to Eurofins’ global network and technical competencies, we should be able to expand our analytical portfolio and services to benefit all our existing and future clients."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.